AstraZeneca, Ionis report major trial failure with heart disease drug
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AstraZeneca, Ionis report major trial failure with heart disease drug" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Times, Barron's, Bloomberg.com and The Guardian. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 131d ago.
Quick answers
Why is "AstraZeneca, Ionis report major trial failure with heart disease drug" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Major drugmaker loses $27 billion in market value after failed trial MarketWatch · 131d ago
- AstraZeneca shares down as drug trial fails to meet target The Times · 131d ago
- AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction Barron's · 131d ago
- Watch AstraZeneca Drug Trial Failure Sends Shares Plunging Bloomberg.com · 131d ago
- Crude oil prices rise again while UK stock market falls, dragged down by AstraZeneca The Guardian · 131d ago
- AstraZeneca, Ionis report major trial failure with heart disease drug STAT · 131d ago
Topics
Related trends
New drug could be cure for common cause of high blood pressure
EU medicines panel recommends AstraZeneca's baxdrostat for uncontrolled hypertension, while new research suggests a potential cure for hormone-driven high blood pressure.
New treatment may cure common hormonal cause of high blood pressure
A small study found that extended treatment with the aldosterone synthase inhibitor baxdrostat led to sustained blood pressure reduction for up to two years after patients stopped taking the drug.
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca reportedly made a $10 billion acquisition offer for obesity drugmaker Rhythm Pharmaceuticals.
AstraZeneca CEO strikes bullish tone on pipeline as stock rallies
AstraZeneca unveils a $1.5 billion savings drive, pledges no layoffs and sees profits surge, sparking a bullish CEO outlook and a share‑price rally.
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is showcasing a new portfolio of targeted cancer therapies, featuring a stomach cancer drug that significantly extended patient survival times.
Astra Doesn’t Need a Deal for Growth Beyond 2030, CEO Says
AstraZeneca asserts independence for post-2030 growth while investing over $1 billion in a new robotics-driven R&D hub in Cambridge, Massachusetts.